Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Orgenesis stock

Own Orgenesis stock in just a few minutes.

Orgenesis Inc is a biotechnology business based in the US. Orgenesis shares (ORGS) are listed on the NASDAQ and all prices are listed in US Dollars. Orgenesis employs 111 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Orgenesis

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ORGS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Orgenesis share price

Use our graph to track the performance of ORGS stocks over time.

Orgenesis shares at a glance

Information last updated 2021-04-23.
52-week range$4.30 - $8.30
50-day moving average $6.23
200-day moving average $5.62
Wall St. target price$9.00
PE ratio 17.517
Dividend yield N/A (0%)
Earnings per share (TTM) $0.29

Buy Orgenesis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Orgenesis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Orgenesis under- or over-valued?

Valuing Orgenesis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Orgenesis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Orgenesis's P/E ratio

Orgenesis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Orgenesis shares trade at around 18x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Orgenesis financials

Revenue TTM $7.7 million
Gross profit TTM $7.7 million
Return on assets TTM -69.85%
Return on equity TTM -211.96%
Profit margin 14.51%
Book value $2.18
Market capitalisation $130 million

TTM: trailing 12 months

Shorting Orgenesis shares

There are currently 753,012 Orgenesis shares held short by investors – that's known as Orgenesis's "short interest". This figure is 37.8% up from 546,620 last month.

There are a few different ways that this level of interest in shorting Orgenesis shares can be evaluated.

Orgenesis's "short interest ratio" (SIR)

Orgenesis's "short interest ratio" (SIR) is the quantity of Orgenesis shares currently shorted divided by the average quantity of Orgenesis shares traded daily (recently around 189675.56675063). Orgenesis's SIR currently stands at 3.97. In other words for every 100,000 Orgenesis shares traded daily on the market, roughly 3970 shares are currently held short.

However Orgenesis's short interest can also be evaluated against the total number of Orgenesis shares, or, against the total number of tradable Orgenesis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Orgenesis's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Orgenesis shares in existence, roughly 30 shares are currently held short) or 0.0326% of the tradable shares (for every 100,000 tradable Orgenesis shares, roughly 33 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Orgenesis.

Find out more about how you can short Orgenesis stock.

Orgenesis share dividends

We're not expecting Orgenesis to pay a dividend over the next 12 months.

Have Orgenesis's shares ever split?

Orgenesis's shares were split on a 1:12 basis on 15 November 2017. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Orgenesis shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Orgenesis shares which in turn could have impacted Orgenesis's share price.

Orgenesis share price volatility

Over the last 12 months, Orgenesis's shares have ranged in value from as little as $4.3 up to $8.3. A popular way to gauge a stock's volatility is its "beta".

ORGS.US volatility(beta: 1.27)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orgenesis's is 1.2653. This would suggest that Orgenesis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Orgenesis overview

Orgenesis Inc. , a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. sThe company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site